Merck ordered into mediation in Fosamax litigation; Valeant expands B + L manufacturing;

@FiercePharma: Top-read special report this weekend: The top 10 pharma companies by 2013 revenue. More | Follow @FiercePharma

@EricPFierce: Analysts propose hookups for troubled Wockhardt even though execs insist it is not for sale. FiercePharmaManufacturing story | Follow @EricPFierce

@CarlyHFierce: ICYMI Friday: New problems at $GSK flu vaccine plant will impact U.S., Canada orders. Article | Follow @CarlyHFierce

> After several years of litigation over femur fractures allegedly caused by osteoporosis drug Fosamax, a New Jersey federal judge has ordered maker Merck ($MRK) and plaintiffs to mediate. Report (sub. req.)

> Valeant Pharmaceuticals ($VRX) will open new manufacturing lines at Bausch + Lomb, with the $106 million addition is expected to result in 100 new jobs. More

> India's Elder Pharma is looking to increase its footprint in the dermatology space. Report

> Endo ($ENDP) has launched an authorized generic of testosterone gel Fortesta. Release

> A pair of long-term studies has confirmed the safety of Bayer's Adempas in patients with chronic thromboembolic pulmonary hypertension (CTEPH) and pulmonary arterial hypertension (PAH). Release

Medical Device News

@FierceMedDev: ICYMI: Medtronic receives CE mark for upgraded CoreValve TAVR. Report | Follow @FierceMedDev

@VarunSaxena2: UPDATED with CEO comments: Will little-known company's inhaled candidate take down InterMune-Roche's pirfenidone? Report | Follow @VarunSaxena2

@MichaelGFierce: CYMI: UO, Berkeley team tailors ultrathin peptoid nanosheets for delivery using oil and water. More | Follow @MichaelGFierce

@EmilyWFierce: French devicemaker Carmat outfits second patient with artificial heart, forges ahead with clinical trials. Story | Follow @EmilyWFierce

> J&J ordered to fork over $3.27M in vaginal mesh case. Article

> FDA clears Otoharmonic's iPad/iPod app that treats tinnitus. Story

Biotech News

@FierceBiotech: You buy a Type 1 diabetes drug in PhIII for $20M in cash and stock and you're "shocked" by trial fraud. Really $HPTX? You didn't suspect? | Follow @FierceBiotech

@JohnCFierce: Running some readership numbers for the year. 70% North America, 18% Europe and 10% Asia, which is a bump for Europe. | Follow @JohnCFierce

@DamianFierce: Hyperion says it was duped into signing a $570M deal for an Israeli biotech. Story | Follow @DamianFierce

@EmilyMFierce: More misplaced pathogens, toxins found in NIH, FDA labs. More from The Washington Post | Follow @EmilyMFierce

> AstraZeneca's self-styled 'blockbuster' benralizumab tanks in severe COPD study. More

> FDA warning dampens Keryx's parade for newly approved kidney drug. Report

> A respiratory expert undermines GSK's case for new asthma drug mepolizumab. Article

CRO News

> AMRI buys into proteomics to expand its discovery services. Report

> Big Pharma supergroup dishes on de-personalizing clinical data. Story

> CRO Ricerca plans to shed its staff if it can't find a buyer. Article

> Venn lands a $3.1M deal to study a bioresorbable stent. Item

> Catalent eyes another big year after a blockbuster IPO. More

Biotech IT News

> Edico sells its first Dragen bioinformatics processor. More

> George Church talks open data with The Economist. Item

> Propeller Health raises $14.5M to develop its smart inhaler. News

> Apple bars health apps from using iCloud, acting as medical devices. Story

> Big Pharma consortium releases guide to redacting trial data. Article

Animal Health News

> USDA gives conditional approval for Zoetis PEDv vaccine. More

> South Korea lifts ban on zilpaterol feed additives in beef. Report

> Ceva Animal Health expanding into swine market. Story

> Perdue says its chick hatcheries are now antibiotic-free. Article

> Kentucky Horse Racing Commission looking into regulating compounders. Item

And Finally... Why aren't Google ($GOOG) and AbbVie ($ABBV) doing their anti-aging research in AbbVie's home state of Illinois? Story

Suggested Articles

In an era of limited access to key decision makers, how are you mobilizing your field force to communicate the value of your brands and real-world evidence?

Novo Nordisk’s Ozempic is off to a blazing start, and the company just threw more fuel on the fire with a pair of trial wins.

Biosims to Roche's Big 3 cancer drugs will chisel out a $10 billion sales gap by 2023, but newer meds could chip in $16.3 billion, the drugmaker says.